|
|
|
|
Adagene Inc (NASDAQ: ADAG) |
|
Price: $1.9400
$0.06 
3.191%
|
| Day's High:
| $1.98
| Week Perf:
| 4.86 %
|
| Day's Low: |
$ 1.86 |
30 Day Perf: |
10.23 % |
| Volume (M): |
27 |
52 Wk High: |
$ 3.58 |
| Volume (M$): |
$ 52 |
52 Wk Avg: |
$2.13 |
| Open: |
$1.96 |
52 Wk Low: |
$1.33 |
|
|
| Market Capitalization (Millions $) |
109 |
| Shares
Outstanding (Millions) |
56 |
| Employees |
77 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-33 |
| Cash Flow (TTM) (Millions $) |
-25 |
| Capital Exp. (TTM) (Millions $) |
0 |
Adagene Inc
Company Address: 4F, Building C14, No. 218 Suzhou 215123
Company Phone Number: 87773632 Stock Exchange / Ticker: NASDAQ ADAG
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Thu, Nov 7 2024 3:01 PM UTC
New Insights into Adagene s ADG126 and Implications for Financial HealthAt the recently concluded Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, Adagene Inc. presented groundbreaking data that highlights the significant promise of its investigational drug, ADG126 (Muzastotug), particularly in its ability to enhance the therapeutic index against various canc...
|
| Clinical Study
Published Mon, Sep 16 2024 7:01 AM UTC
Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with KEYTRUDA (Pembrolizumab) in Advanced/Metastatic Microsatellite-Stable Colorectal Cancer: Insights from ESMO Congress Recent advancements in the treatment of advanced/metastatic microsatellite-stable (MSS) colorectal cancer (CRC) hold promising implications for improved patie...
|
| Adagene Inc
Adagene Inc's financial results for the October to December 31, 2023 fiscal interval show a significant improvement compared to the previous year. The company reported a narrower loss of $-0.35 per share, compared to $-1.48 a year ago. This indicates that the company has been able to reduce its deficit per share, which is a positive sign for investors.
In addition, Adagene Inc saw a substantial increase in revenue, with a 94.9% rise to $18.11 million from $9.29 million in the same period last year. This growth in revenue is a promising sign for the company's future financial performance.
|
| Product Service News
Published Fri, Feb 9 2024 11:00 AM UTC
Adagene, a leading biotechnology company, recently announced the progress and expansion of its clinical collaboration program for their promising drug, ADG126 (also known as muzastotug), in combination with KEYTRUDA (pembrolizumab), targeting patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC). This collaboration aims to further demonstrate the effic...
|
| Clinical Study
Published Tue, Jan 16 2024 10:01 PM UTC
The treatment landscape for metastatic microsatellite-stable (MSS) colorectal cancer (CRC) has been evolving rapidly, with immunotherapy playing a significant role. In a recent study, Adagene presented interim results highlighting the potential of their novel therapy, masked anti-CTLA-4 SAFEbody ADG126 (muzastotug), in combination with pembrolizumab. This article aims to pro...
|
| Per Share |
Current |
| Earnings (TTM) |
-0.59 $ |
| Revenues (TTM) |
0 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.51 $
|
| Book Value |
0.9 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.59 $
|
| Revenues (TTM) |
0 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.51 $
|
| Book Value |
0.9 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
1.17%